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Summary The management of patients with hypertrophic cardiomyopathy (HCM) has evolved
markedly over the past 20 years, particularly with the rising number of indications for
implantable cardiac deﬁbrillators (ICDs) and alcohol septal ablation (ASA). However, medi-
cal therapies targeted to improve quality of life are underused; when resting and/or exercise
obstruction is present, an incremental and additive approach should be used based on a high
dosage of beta-blockers, verapamil and/or disopyramide. Radiofrequency catheter ablation of
atrial ﬁbrillation or A—V node has been proposed in some instances. Treatment of syncope or
presyncope due to an abnormal blood pressure response during exercise remains challenging.
Only patients with obstruction who remain severely symptomatic despite maximal medical ther-
apy should be considered for invasive procedures, including dual-chamber (DDD) pacing, ASA
or surgery. The reported complication rates of ASA (essentially complete A—V block, incidence
above 5—10%, with mortality rates ranging from 0—4%) and the beneﬁts at medium-term follow-
up appear comparable to those observed after myectomy, which, according to guidelines, should
remain the primary treatment for most severely symptomatic drug-refractory young patients
with obstruction. While the overall survival of patients with HCM is similar to that of the gen-
eral population, detection of patients at high risk of sudden cardiac death remains challenging,
particularly in the young, and indications for ICDs in high risk patients without prior cardiac
d family-orientated.arrest should be patient- an
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Résumé La prise en charge des patients porteurs de cardiomyopathie hypertrophique (CMH) a
remarquablement évolué ces 20 dernières années, particulièrement en ce qui concerne le nom-
bre croissant d’indications de déﬁbrillateur automatique implantable (DAI) et d’alcoolisation
septale (AS). Cependant, les traitements médicaux ayant pour but d’améliorer la qualité de vie
sont souvent sous-employés. Lorsqu’une obstruction est présente au repos ou à l’effort, une
approche incrémentielle et additive devrait être employée, basée sur de fortes posologies de
bêtabloquants, vérapamil et/ou disopyramide. L’ablation par radiofréquence d’une ﬁbrillation
auriculaire ou du nœud auriculoventriculaire (AV) a été proposée dans certains cas. La prise
en charge des syncopes ou lipothymies par chute tensionnelle d’effort reste décevante. Seuls
les patients obstructifs restant sévèrement symptomatiques en dépit d’un traitement médical
maximal devraient être évalués pour porter l’indication de procédures invasives, stimulation
cardiaque double chambre, AS ou chirurgie. Les taux de complications de l’AS rapportés dans
la littérature, essentiellement bloc AV complet, sont supérieurs à 5—10% avec des taux de mor-
talité de 0—4% tandis que les bénéﬁces à moyen terme paraissent comparables à ceux observés
après myectomie. La chirurgie, selon les recommandations récentes, devrait être préférée chez
la plupart des jeunes patients obstructifs réfractaires aux médicaments. Alors que la survie
globale des patients avec CMH est identique à celle de la population générale, la détection
des patients à haut risque de mort subite, notamment les plus jeunes, reste difﬁcile, et les
indications de DAI chez les patients à haut risque sans antécédent d’arrêt cardiaque devraient
être adaptées à chaque cas et au contexte familial.
© 2009 Elsevier Masson SAS. Tous droits réservés.
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ypertrophic cardiomyopathy (HCM) is now recognized as a
ot uncommon ﬁnding in the general population (one per
00 individuals). This discovery, combined with the publi-
ation of multiple pivotal studies over the past 20 years
oncerning the pathophysiology, genetics, natural history
nd causes of HCM, and the risk factors for death, has led
o a better understanding of the disease by the medical
ommunity and to an increasing number of patients being
iagnosed with HCM [1]. At the same time, the management
f patients with HCM has evolved: while medical manage-
ent and, exceptionally, surgery were the only options for
period of 40 years, electrical therapies including dual-
hamber (DDD) pacing or implantable cardiac deﬁbrillators
ICDs) and alcohol septal ablation (ASA) have emerged as
romising new techniques, with an exponentially rising num-
er of indications. In parallel, whereas primarily clinical
ardiologists (and echocardiographists) have been involved
n the diagnosis and treatment of HCM, nowadays interven-
ional rhythmologists and interventional cardiologists are
rogressively taking a role, often being asked for ﬁrst-line
anagement advice for this condition. Times are therefore
hanging for patients with HCM, in a manner similar per-
aps to that for coronary artery disease when angioplasty
merged as a new therapeutic modality. However, one prob-
bly needs to temper excessive enthusiasm and bear in mind
ome clinically relevant statements before treating these
atients. In this report, therefore, we provide an overview
f HCM and the treatment options currently being used, and
ffer suggestions for future clinical research.
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[hile HCM is often a benign disease,
udden death is more frequent in the
oung
he overall survival of patients with HCM is similar to that of
he general population. Moreover, mortality appears to have
ecreased over the past decades, at a rate of approximately
—2% per year [1—4]. Regarding this issue, the primary goal
f any treatment in most patients (who are only moderately
ymptomatic) should be ‘‘primum non nocere’’, or ‘‘ﬁrst,
o no harm’’.
Studies have shown that three causes of death are
redominant in patients with HCM: sudden cardiac death
SCD) due to ventricular arrhythmias (VAs), irrespective
f the initial trigger (Fig. 1) [1—5]; heart failure often
receded by permanent atrial ﬁbrillation; and stroke in
he setting of paroxysmal or permanent atrial ﬁbrillation
2.5% per year) [1—3]. Bacterial endocarditis remains a
eal risk, essentially in patients with obstruction. While
ach cause of death occurs at a frequency of less than
% per year, the risk of SCD remains markedly elevated
n the youngest patients, reaching up to 6% per year in
hose aged 20—30 years [2]. Moreover, SCD frequently occurs
s the ﬁrst clinical event (in about 75% of all SCDs) in
symptomatic or mildly symptomatic (New York Heart Asso-
iation [NYHA] functional class I or II) patients, and less
requently during moderate or severe exercise (about 15%,
ustifying the exclusion of patients from any competitive
port), and sometimes even while the individual is in bed
2].
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Figure 1. Mechanisms of sudden cardiac death in hypertrophic
cardiomyopathy [1—4]. While precipitant factors are usual and can
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tbe detected by noninvasive screening procedures (Holter electro-
cardiogram, exercise test, etc.), sustained ventricular tachycardia
or primary ventricular ﬁbrillation can be the ﬁrst and last event [5].
Detection of patients at high risk of death
remains challenging
Among the suggested risk factors for SCD (Table 1), ﬁve have
been proposed as major markers, but these are essentially
relevant for young adults before the age of 40—50 years:
• family history of premature SCD;
• marked (or malignant) left ventricular hypertrophy
(≥ 30mm);
• unexplained syncope or presyncope;
Table 1 Proposed risk factors for sudden cardiac death
in hypertrophic cardiomyopathy.
Risk factors
Classical
Prior cardiac arrest or spontaneous sustained
ventricular tachycardia
Unexplained syncope
Family history of premature sudden cardiac death
Maximal LVWT≥ 30mm
Exercise ABPR < 25mmHg
Spontaneous nonsustained VT≥ 120 bpm
Possible in individuals
Atrial ﬁbrillation
Resting outﬂow tract obstruction ≥ 30mmHg
Myocardial ischaemia or coronary artery disease
Extensive late gadolinium enhancement on magnetic
resonance imaging
Troponin T and I mutations
Intense physical exertion
ABPR: abnormal blood pressure response during upright
exercise; LVWT: left ventricular wall thickness.
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nonsustained ventricular tachycardia (≥ 120 bpm);
abnormal blood pressure response during upright exercise
(< 20—30mmHg rise during peak exercise; but of no value
in children or young adolescents).
While the negative predictive values for each of these
arkers are high (> 90%), their positive predictive values are
ow (< 20%), weakening their role in the stratiﬁcation of risk
n individual patients [1,2]. A multifactorial approach may
e more efﬁcient, as the combination of at least three major
isk factors (present in only 5% of patients) has helped to
dentify a subgroup with a markedly elevated risk of SCD
6% per year) [6].
Other markers have been proposed recently (Table 1),
ased on the results from paced electrocardiographic frac-
ionation analysis [7] and cardiac magnetic resonance
CMR). The 5-year probability of SCD given the presence of
ﬁbrous scar on CMR has been estimated to reach approx-
mately 11% versus 0.7% in its absence [8]. It remains that
CD can occur at all ages, in asymptomatic patients with no
lassical markers of SCD, and even in the absence of left
entricular hypertrophy.
Heart failure is an important cause of death at all ages
ut particularly in the elderly population; it is accelerated
y the development of permanent atrial ﬁbrillation, which
s often poorly tolerated in patients with stiff ventricles and
ometimes requires rapid cardioversion [9]. An association
etween the presence of resting obstruction (≥ 30mmHg)
nd mortality (twofold at 10 years) has been demonstrated
ecently, essentially due to a marked increase in the rate
4.4-fold) of progression towards severe functional limita-
ion and death from heart failure [10]. In the same study,
he importance of the gradient did not correlate with the
ncidence of death, while others have suggested an associa-
ion between elevated left ventricular outﬂow tract (LVOT)
radient (> 70mmHg) and death (four-fold) [11].
Proposed determinants of stroke [3,9,12] in HCM are
trial ﬁbrillation, dilated left atrium (exponential rise above
5mm or 34mL/cm2 by echocardiography), advanced age
> 60 years), female sex, LVOT obstruction and existence
f a prothrombotic state (hypercoagulation and inﬂamma-
ory process), which has been noted in patients with HCM,
articularly in the obstructive forms [13]. Atrial ﬁbrilla-
ion is associated with reduced survival and progression to
evere heart failure. Prophylactic anticoagulation is then
andatory in patients with paroxysmal or chronic atrial
brillation.
edical therapies targeted to improve
uality of life are often underused
n symptomatic patients, when resting and/or exercise LVOT
bstruction is present (about 70% of all patients), one ﬁrst
ypothesizes that symptoms are due mainly to the gradient,
nd the primary aim is therefore to decrease the resting
nd/or exercise gradient [14]. In fact, even if the resting
radient only poorly correlates with functional limitation, it
ncreases symptoms through reduced stroke volume (leading
o syncope), increased left ventricular pressure and micro-
irculatory abnormalities (leading to angina), increased
ystolic anterior motion of the mitral valve and mitral regur-
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itation and load-dependant diastolic dysfunction (leading
o dyspnoea) [15,16].
In hypertrophic obstructive cardiomyopathy (HOCM),
eta-blockers should be preferred as the ﬁrst-line ther-
py (decreasing essentially the provoked gradient) while
erapamil should be chosen in patients with contraindi-
ations to beta-blockers or in the absence of obstruction
improving diastolic function). A high daily dosage of each
rug should be achieved through progressive increases in
he dosage, which is scarcely achieved, corresponding to
20—480mg of propanolol (and up to 600mg) or 480mg of
erapamil. This progressive approach usually limits the prob-
ems of tolerance. Lower dosages may be used when both
rugs are prescribed concomitantly. As a third-line therapy,
he association of one of the former drugs with disopyra-
ide (200—600mg), which also decreases contractility and
eart rate, is efﬁcient in decreasing the resting gradient
hen patients remain symptomatic along with the pres-
nce of a residual resting gradient. It is also the drug of
hoice (with amiodarone) to prevent recurrence of atrial
brillation [15—18]. Disopyramide appears not to increase
ortality [19], but it should never be used with amio-
arone because when combined these drugs have a risk of
nduced VA. Finally, adjunctive treatment with a low-dose
iuretic, which may increase obstruction, is sometimes nec-
ssary when exercise dyspnoea persists along with markedly
levated left ventricular end-diastolic pressure (measured
nvasively or suspected at Doppler echocardiography when
he ratio of E-wave velocity at the mitral inﬂow on E velocity
t the mitral annulus exceeds 12—15 cm/s [20]. This incre-
ental and additive approach, while quite efﬁcient and
ecommended in recent guidelines [15—18], is scarcely used
n current clinical practice. Only patients with HOCM who
emain severely symptomatic (with severe dyspnoea and/or
ngina, or recurrent syncope) despite maximal medical ther-
py should be considered for invasive procedures including
ermanent DDD pacing with a short atrioventricular (A—V)
elay, ASA or cardiac surgery [17].
ndications for electrical therapies should
e patient-orientated
ith regard to pacing, randomized, controlled studies with
elatively short follow-up (3months on the active DDDmode)
ave produced controversial results, some in favour of DDD
acing (fewer symptoms and gradient versus AAI mode) [21].
thers, however, show either a moderate positive effect on
he gradient but no difference in exercise duration or peak
xygen consumption [22], or the absence of any positive
ffect (while the same study reported 40% of responders
ged over 65 years) [23]. Thus, the indications of DDD pac-
ng dramatically decreased within the past 10 years. If some
atients with HOCM undoubtedly beneﬁt from pacing, clini-
al or echocardiographic variables fail to predict a positive
esponse to DDD pacing [24], which is probably critically
ependant of the setting of the A—V delay just after implan-
ation and during follow-up. According to recent guidelines,
ermanent pacing may be considered in medically refrac-
ory symptomatic patients with HCM and signiﬁcant resting
r provoked LVOT obstruction (Class IIB, level of evidence: A)
t
p
i
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25]. This is even more so in HOCM patients with coexisting
dvanced conduction system disease with an independent
ndication for an ICD, or discussion of septal ablation with
he presence of left bundle branch block [15].
With regard to ICDs, rates of interventions for VAs in
ulticentre HCM registries reach up to 10% per year in
atients with a history of aborted SCD and 4% per year in
igh risk patients without prior cardiac arrest (sometimes
p to 10 years after implantation!) [26,27]. According to
he 2008 guidelines from the American College of Cardiol-
gy/American Heart Association/Heart Rhythm Society [25],
n ICD should be implanted if the patient has had a prior
ardiac arrest (Class I, level of evidence: C), and is rea-
onable for patients with sustained ventricular tachycardia
r if one or more risk factors for SCD is present (IIa, C). It
ay be considered in patients with syncope in whom inva-
ive and noninvasive investigations have failed to deﬁne a
ause (IIb, C) or in patients with familial HCM associated
ith SCD (IIb, C) (level of evidence C means that very limited
opulations were studied for this purpose). As 25% and 20%
f all patients with HCM have only one or two risk factors,
espectively [6], and taking into account that most of these
atients will not die suddenly, it would not be reasonable to
mplant ICDs systematically in this population: instead, man-
gement should be patient- and family-orientated. A good
xample is the adolescent or young adult with a single major
isk factor (such as multiple SCDs at a young age in ﬁrst-
egree relatives or malignant hypertrophy or nonsustained
entricular tachycardia on Holter electrocardiographic mon-
toring) for whom no deﬁnite rules can be provided. One
ust bear in mind that, in a recent cohort of 506 patients,
mplantation complications occurred in 27% of cases, with
ne (0.2%) death linked directly to the procedure [27]. Indi-
ations for ICDs in children with HCM are the same as those
or adults, with careful consideration of the risks associated
ith implantation, which increase with small body size [25].
lcohol septal ablation might be overused
17]
ince 1994, when Ulrich Sigwart ﬁrst introduced ASA through
he ﬁrst septal branch into clinical practice [28], the tech-
ique has become an important therapeutic option for
everely symptomatic (NYHA class III or IV) patients with
OCM despite maximal medical therapy, with an LVOT gra-
ient greater than or equal to 50mmHg (either at rest
r during or after exercise) and predominant upper septal
ypertrophy (≥ 18mm without important structural abnor-
alities in the mitral valve) without associated signiﬁcant
oronary atherosclerosis [17]. The increase in number of
ndications appears to be due to the relative (or apparent)
implicity and wide availability of the technique outside of
CM reference centres, as well as to the important propor-
ion of HCM patients with resting (25%) or exercise-provoked
> 50%) gradient [14] and the less-invasive nature of the
echnique compared with surgical myectomy.
The ASA technique, which combines coronary angiogra-
hy with contrast echocardiography, has now been standard-
zed [29—32]. Contrast echocardiography (usually 1—2mL of
50mg/mL solution of Levovist® injected into the septal
445
Table 2 Outcome of alcohol septal ablation for obstruc-
tive hypertrophic cardiomyopathy. Study involving 138
patients from a single, tertiary referral centre (Mayo
Clinic). Adapted from Sorajja et al. [33].
Procedural results Median
(interquartile range)
Number of injected septal
arteries
1.0 (1.0)
Volume of ethanol (mL) 1.8 (0.5)
Fluoroscopic time (min) 30 (16)
Procedure time (min) 137 (48)
Contrast volume (mL) 150 (66)
Change in left ventricular outﬂow tract gradient (mmHg)
Baseline 80 (50)
Post ablation 10 (19)
One-month clinical events
Pacemaker implantation 20.4%
Cardiac tamponade 3.5%
Urgent cardiac surgery 1.3%
Resuscitated sudden
cardiac death
1.3%
Stroke 0.7%
Sustained ventricular
tachycardia
0.7%
Death from heart failure 0.7%
S
s
The presence of intrinsic structural abnormalities of the
mitral valve may be responsible for obstruction and mitral
regurgitation [36]. These include increased leaﬂet thick-
ness, surface and length, prolapse and abnormal papillary
Table 3 Comparison between beneﬁts and side-effects
of surgical myectomy and alcohol septal ablation (ASA).
Creation of a scar after ASAmay be arrhythmogenic, lead-
ing to restriction of ablation indications in the young.
Parameter Myectomy Ablation
Operative mortality 1—2% 2—4%
Gradient reduction (at
rest)
To < 10mmHg To < 25mmHg
Symptoms Decreased Decreased
Exercise limitation Decreased Decreased
Effective whatever the
anatomy
Usually No
Pacemaker 2% 5—10% up to
30%
Estimated patient
selection
< 5% 15—20%
Long-term risk of SCD Very low UncertainNew trends in treatment of hypertrophic cardiomyopathy
artery under echocardiographic control in the apical four-
chamber view) helps to identify the core of alcohol accu-
mulation (but underestimates the tissue diffusion of alcohol)
and checks for the absence of perfusion of erratic territories
(such as the mitral or tricuspid papillary muscles or the right
ventricular free wall). While the upper hypertrophied sep-
tum is usually perfused by the ﬁrst septal branch, 5—30%
of candidates present a nonsuitable septal branch. Fur-
thermore, in 10—30% of cases, successful ASA necessitates
selective administration of alcohol into more than one sep-
tal branch, initially or during a second procedure (as is the
case for 10% of patients). There has been much discussion
concerning the ideal volume and ﬂow rate of alcohol infu-
sion; the initial use of a 2—5 cm3 infusion over a period of 30 s
has been replaced progressively by smaller quantities (about
1—2 cm3) over a longer period (30—60 s), with a slow continu-
ous infusion to avoid A—V block and overspill from the target
territory. The balloon is usually kept inﬂated for at least
5min after the end of infusion to allow clot organization
and prevent vascular runoff of alcohol. A temporary pace-
maker needs to be inserted during the procedure, remaining
in place for the following 3—4days as delayed A—V block
(10—25% of all procedures) can arise suddenly after 48 h
[31]. The favourable effects of ASA typically progress over
time in three distinct phases (not observed consistently),
with periprocedural abolition of the gradient (coagulation
necrosis), early (1—3days) postprocedural recurrence (ede-
matous phase for 5—10 days) and late permanent decrease
of the gradient (scarred and thin myocardium) [31].
Procedural success, deﬁned as at least 50% reduction in
the resting gradient or decreased provoked gradient with
residual resting gradient less than 20mmHg, occurs in more
than 80% of cases. Up to 50% of patients are in NYHA class I
after the procedure, along with improved exercise capacity
and VO2 peak, decreased septal thickness and ventricular
remodelling (decreased mass and increased dimensions)
combined with improvement in diastolic function indices,
and decreased left atrial size [28,32,33]. The complication
rates of ASA (Table 2) range from 5% to 30%—–essentially
complete A—V block (the incidence of which has decreased
(> 5—10%) with the use of ultrasonic guidance and lower
dose of alcohol)—–with mortality rates ranging from 0—4%
(mean: 1.9%) [16]. Medium-term follow-up data are now
available, and the beneﬁts appear comparable to those
observed after myectomy, with an overall mortality-free
survival, including ICD discharge for VAs, of 94% at 2 years
and 88% at 4 years [15].
According to recent guidelines, surgical septal myectomy
should be the primary treatment option for most severely
symptomatic drug-refractory patients with HOCM, particu-
larly in the young, while ASA is an alternative for patients
at increased operative risk, for those without access to
expert surgical centres or who refuse operation after both
options have been discussed fully [15,34]. Over the past 10
years, surgical mortality related to isolated myectomy has
approached 1% in major expert centres, with low procedure-
related morbidity (2—3%), excellent late results (90%
improved) and high long-term survival rates [35]. Surgery
remains the procedure of choice in cases of associated struc-
tural mitral valve abnormalities or coronary artery disease,
in patients requiring the Maze procedure to cure atrial ﬁb-
rillation or eventually in cases of unsuccessful ASA (Table 3).Sudden death 0.7%
All deaths 1.4%
tructural mitral valve abnormalities
hould be trackedAvailable follow-up #50 years #10 years
Intramyocardial scar No Yes
SCD: sudden cardiac death; #: approximately.
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uscle insertion in about 20% of patients with HOCM
15,37]. Anterior malposition of the mitral valve apparatus,
hich is frequent in HCM, together with leaﬂet elonga-
ion, may explain persistence of systolic anterior motion and
bstruction after ASA [38,39]. When important, such abnor-
alities represent a contraindication to ASA and surgery
hould be considered, which may include speciﬁc proce-
ures targeted to the mitral valve such as valvuloplasty or
eplacement.
ew hopes
n HCM, randomized studies concerning medical therapy,
SA or surgery are lacking due to the relative scarcity of
he disease. Angiotensin receptor blockers [40] and statins
41] have shown some efﬁcacy in preventing left ventricular
ypertrophy in transgenic animals. Data concerning treat-
ent of syncope or presyncope due to an abnormal blood
ressure response during exercise are lacking, but some
ave proposed the use of a dopamine-receptor antagonist in
his setting [42]. Radiofrequency catheter ablation of atrial
brillation seems to be possible in HCM, with better results
n cases of paroxysmal versus permanent atrial ﬁbrillation
43]. However, the risk associated with the technique and
ecurrence over the medium term should not be ignored,
hile A—V node ablation with pacemaker implantation may
e a safe alternative. As another option to ASA, septal artery
mbolization with coils has been proposed recently as a
ess-invasive technique compared with ASA, with a lower
ate of complications and A—V block, along with an appar-
ntly smaller beneﬁt in the LVOT gradient, probably due
o the development of collateral blood ﬂow [44]. Finally,
eart transplantation can be performed in patients with HCM
nd end-stage evolution with systolic dysfunction, with sim-
lar results to those from patients with idiopathic dilated
ardiomyopathy [45]. Gene therapy remains the ultimate
oal as the turnover of sarcomeric proteins is relatively
apid.
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